Page 1211 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 86 Glucocorticoids 1175

14. Palmowski Y, Buttgereit T, Dejaco C, et al. The “official view” on 27. van de Goes M, Jacobs J, Boers M, et al. Monitoring adverse events of
glucocorticoids in rheumatoid arthritis. A systematic review of low-dose glucocorticoid therapy: EULAR recommendations for clinical
international guidelines and consensus statements. Arthritis Care Res trials and daily practice. Ann Rheum Dis 2010;69:1913–19.
(Hoboken) 2017;69:1134–41. 28. Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for
15. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for steroid-induced osteoporosis. Cochrane Database Syst Rev
systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370–7. 2016;(10):CD001347.
16. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in 29. Anwar MA, Saleh AI, Al Olabi R, et al. Glucocorticoid-induced fetal
systemic lupus erythematosus: response to mycophenolate mofetil. Lupus origins of adult hypertension: association with epigenetic events. Vascul
2003;12:630–2. Pharmacol 2016;82:41–50.
17. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid 30. Caplan A, Fett N, Rosenbach M, et al. Prevention and management of
receptors (mGCR) are expressed in normal peripheral blood glucocorticoid-induced side effects: a comprehensive review:
mononuclear cells and upregulated following in vitro stimulation and in gastrointestinal and endocrinologic side effects. J Am Acad Dermatol
patients with rheumatoid arthritis. FASEB J 2004;18:70–80. 2017;76:11–16.
18. Buttgereit F, Saag K, Cutolo M, et al. The molecular basis for the 31. Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with
effectiveness, toxicity, and resistance to glucocorticoids: focus on the immunosuppressive drugs and glucocorticoids for lupus nephritis: a
treatment of rheumatoid arthritis. Scand J Rheumatol 2005;34:14–21. systematic review and network meta-analysis. BMC Med 2016;14:137.
19. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous 32. Joseph RM, Hunter AL, Ray DW, et al. Systemic glucocorticoid therapy
glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63:1–9. and adrenal insufficiency in adults: a systematic review. Semin Arthritis
20. Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid Rheum 2016;46:133–41.
metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204–10. 33. Black RJ, Hill CL, Lester S, et al. The association between systemic
21. Buttgereit F, Zhou H, Kalak R, et al. Transgenic disruption of glucocorticoid use and the risk of cataract and glaucoma in patients with
glucocorticoid signaling in mature osteoblasts and osteocytes attenuates rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE
K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum 2016;11:e0166468.
2009;60:1998–2007. 34. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological
22. da Silva JAP, Jacobs JWG, Kirwan JR, et al. Long-term glucocorticoid rhythms: prednisone chronotherapy shows sustained efficacy in
therapy in rheumatoid arthritis: an evidence-based review of potential rheumatoid arthritis. Ann Rheum Dis 2010;69:1275–80.
adverse effects. Ann Rheum Dis 2006;65:285–93. 35. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial
23. Shane E, Rivas M, McMahon JD, et al. Bone loss and turnover after and side effects of steroid therapy: lessons from conditional knockout
cardiac transplantation. J Clin Endocrinol Metab 1997;82:1497–506. mice. Mol Cell Endocrinol 2007;275:98–108.
24. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on 36. Schacke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186,
radiological progression in rheumatoid arthritis. Cochrane Database Syst a novel, selective glucocorticoid receptor agonist for the topical treatment
Rev 2007;(1):CD006356. of inflammatory skin diseases. Br J Pharmacol 2009;158:1088–103.
25. Graudal N, Jurgens G. Similar effects of disease modifying anti rheumatic 37. Inui K, Koike T. Combination therapy with biologic agents in rheumatic
drugs, glucocorticoids and biologic agents on radiographic progression in diseases: current and future prospects. Ther Adv Musculoskelet Dis
rheumatoid arthritis: meta-analysis of 70 randomised placebo or drug 2016;8:192–202.
controlled studies including 112 comparisons. Arthritis Rheum 38. Krasselt M, Baerwald C. Efficacy and safety of modified-release
2010;62:2852–63. prednisone in patients with rheumatoid arthritis. Drug Des Devel Ther
26. Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone 2016;10:1047–58.
hexacetonide in knee osteoarthritis: factors influencing the clinical
response. Ann Rheum Dis 1995;54:379–81.